Core Pathophysiology
Sepsis drives a systemic inflammatory response that massively upregulates tissue factor on monocytes and endothelial cells. This triggers thrombin generation throughout the microcirculation, forming fibrin-rich microthrombi in small vessels. At the same time, the sustained coagulation consumes platelets, fibrinogen, and clotting factors, while secondary fibrinolysis degrades the fibrin that has formed. The clinical result is a paradoxical combination: microvascular thrombosis causing end-organ ischemia, alongside a bleeding tendency from depletion of hemostatic components [1][2].
In this patient, the cool, dusky fingertips reflect microvascular occlusion in the skin, while oozing from intravenous and arterial line sites reflects the consumptive coagulopathy. The laboratory profile fits this dual process: platelets 48 × 10⁹/L, fibrinogen 0.9 g/L, prolonged PT/INR 2.1, prolonged aPTT, and markedly elevated D-dimer. No single alternative in the options explains all five abnormalities simultaneously [1][3].
Why the Other Options Do Not Fit
| Condition | Platelets | Fibrinogen | PT/aPTT | D-dimer | Key Discordant Finding |
|---|---|---|---|---|---|
| Vitamin K deficiency | Normal | Normal | Prolonged | Normal or mildly elevated | Does not consume platelets or fibrinogen; no microthrombosis |
| Heparin-induced thrombocytopenia (HIT) | Low | Normal | Normal | Normal or mildly elevated | Thrombosis without hypofibrinogenemia or prolonged clotting times |
| Immune thrombocytopenia (ITP) | Low | Normal | Normal | Normal | Isolated platelet destruction; no consumption coagulopathy |
| Disseminated intravascular coagulation (DIC) | Low | Low | Prolonged | Markedly elevated | Matches all five abnormalities |
Watch out! HIT typically develops 5–14 days after first heparin exposure, not on day 2. Even when HIT causes thrombosis, it does not lower fibrinogen or prolong the PT/aPTT, because it is an antibody-mediated platelet activation disorder, not a consumptive coagulopathy [2].
Sepsis-Induced Coagulopathy and DIC as a Spectrum
Current understanding frames sepsis-associated coagulopathy as a continuum. Early compensated activation may show only mild laboratory changes, but as the process advances, overt DIC emerges with the classic picture of thrombocytopenia, hypofibrinogenemia, prolonged global clotting times, and high fibrin degradation products. The ISTH overt DIC criteria rely on exactly these parameters, which is why a septic patient with this combination should be recognized as having overt DIC rather than a milder coagulopathy [3].
Key point! In sepsis, DIC is not a separate disease but the end-stage consumptive phase of infection-driven coagulation. The primary management is source control and antimicrobial therapy for the underlying infection, with supportive blood product replacement guided by bleeding risk and laboratory trends [3].
Putting the Clinical Picture Together
The patient’s presentation of fever, flank pain, confusion, hypotension with a MAP of 57 mmHg, tachycardia, tachypnea, and lactate 4.8 mmol/L establishes septic shock from a urinary source. The subsequent development of simultaneous bleeding and microvascular thrombosis, combined with the five characteristic laboratory derangements, is the defining signature of DIC. A low platelet count alone would not distinguish DIC from HIT or ITP; it is the concurrent fall in fibrinogen with prolonged PT and aPTT and a markedly elevated D-dimer that confirms consumptive coagulopathy [1][2].
Suspect disseminated intravascular coagulation when a septic patient develops simultaneous bleeding from line sites and microvascular thrombosis such as dusky, cool extremities. The hallmark laboratory pattern includes thrombocytopenia, hypofibrinogenemia, prolonged PT/aPTT, and markedly elevated D-dimer.
The primary treatment is source control of the underlying infection with appropriate antibiotics and hemodynamic support. Transfusion of platelets, fresh frozen plasma, or cryoprecipitate is reserved for active bleeding or high-risk procedures, not for laboratory abnormalities alone.
Do not confuse DIC with heparin-induced thrombocytopenia, which typically occurs after 5–10 days of heparin exposure and does not cause hypofibrinogenemia or prolonged clotting times. In DIC, heparin prophylaxis alone does not stop the underlying consumptive process.
학습 참고용입니다. 실제 임상은 최신 지침과 소속 기관 프로토콜을 따르세요.